This bill mandates the establishment of a Biotechnology Management Office (BMO) within the Department of Defense (DoD) to enhance the development, acquisition, and sustainment of biotechnology capabilities. The Secretary of Defense must designate a senior official within 90 days and formally charter the BMO under the Deputy Secretary of Defense within 120 days. The BMO will be responsible for maintaining a long-term research, development, acquisition, and sustainment roadmap for biotechnology, and updating DoD policies for the adoption of biotechnology-based products. It will also coordinate efforts across government, industry, and academia, propose options to streamline regulatory and acquisition processes, and support public-private partnerships while identifying workforce and training gaps. This section of the bill is set to terminate on September 30, 2030, and requires a briefing to congressional defense committees on the BMO's scope and implementation plans. Furthermore, the bill amends existing law to explicitly permit the use of Department of Defense research, development, test, and evaluation funds for bioindustrial manufacturing processes, including design and construction activities.